4.61
price down icon2.12%   -0.10
after-market Dopo l'orario di chiusura: 4.60 -0.01 -0.22%
loading
Precedente Chiudi:
$4.71
Aprire:
$4.7
Volume 24 ore:
221.14K
Relative Volume:
0.52
Capitalizzazione di mercato:
$213.56M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-1.7331
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+5.73%
1M Prestazione:
+15.25%
6M Prestazione:
-1.07%
1 anno Prestazione:
-74.30%
Intervallo 1D:
Value
$4.505
$4.7497
Intervallo di 1 settimana:
Value
$4.145
$4.7497
Portata 52W:
Value
$2.235
$19.69

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Nome
4 D Molecular Therapeutics Inc
Name
Telefono
(510) 505-2680
Name
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Name
Dipendente
227
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
FDMT's Discussions on Twitter

Confronta FDMT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
4.61 208.46M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-13 Downgrade BMO Capital Markets Outperform → Market Perform
2024-11-21 Iniziato Morgan Stanley Underweight
2024-09-23 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-04-15 Iniziato Barclays Overweight
2024-02-07 Ripresa Goldman Buy
2023-10-26 Iniziato RBC Capital Mkts Outperform
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-10-18 Aggiornamento Leerink Partners Market Perform → Outperform
2023-07-05 Iniziato Chardan Capital Markets Buy
2023-01-30 Iniziato BMO Capital Markets Outperform
2022-11-18 Iniziato H.C. Wainwright Buy
2022-11-15 Aggiornamento Goldman Neutral → Buy
2022-08-12 Downgrade SVB Leerink Outperform → Mkt Perform
2022-06-22 Iniziato Jefferies Buy
2022-01-04 Iniziato SVB Leerink Outperform
2021-01-05 Iniziato BofA Securities Buy
2021-01-05 Iniziato Evercore ISI Outperform
2021-01-05 Iniziato Goldman Neutral
Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

pulisher
Jul 24, 2025

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

4DMT Reveals New Phase 2 Trial Results for Revolutionary Eye Disease Treatment at Major Conference - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about 4D Molecular Therapeutics Inc. stockUnrivaled growth potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

4D Molecular Therapeutics Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is 4D Molecular Therapeutics Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives 4D Molecular Therapeutics Inc. stock priceMarket-crushing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Popular Stock Recommendations - Newser

Jul 21, 2025
pulisher
Jul 19, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 19, 2025
pulisher
Jul 18, 2025

Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025
pulisher
Jul 17, 2025

4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jul 11, 2025
pulisher
Jul 11, 2025

Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

4D Molecular to layoff about 25% of workforce - MSN

Jul 10, 2025
pulisher
Jul 07, 2025

Promising Penny Stocks To Consider In July 2025 - simplywall.st

Jul 07, 2025
pulisher
Jul 06, 2025

4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat

Jul 06, 2025
pulisher
Jul 05, 2025

Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 05, 2025
pulisher
Jul 04, 2025

4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Nasdaq

Jul 03, 2025
pulisher
Jul 02, 2025

East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals

Jul 02, 2025
pulisher
Jul 02, 2025

4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener

Jul 02, 2025
pulisher
Jul 02, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire

Jul 02, 2025
pulisher
Jun 30, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jun 28, 2025
pulisher
Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025
pulisher
Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025
pulisher
Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for SHLS FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World

Jun 11, 2025

4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):